Pharmacokinetics and safety of rucaparib in patients with advanced solid tumors and hepatic impairment.

ABSTRACT:

Purpose

The poly(ADP-ribose) polymerase inhibitor rucaparib is approved for the treatment of patients with recurrent ovarian and metastatic castration-resistant prostate cancer; however, limited data are available on its use in patients with hepatic dysfunction. This study investigated whether hepatic impairment affects the pharmacokinetics, safety, and tolerability of rucaparib in patients with advanced solid tumors.

Methods

Patients with normal hepatic function or moderate hepatic impairment according to the National Cancer Institute Organ Dysfunction Working Group (NCI-ODWG) criteria were enrolled and received a single oral dose of rucaparib 600 mg. Concentrations of rucaparib and its metabolite M324 in plasma and urine were measured. Pharmacokinetic parameters were compa

SUBMITTER: Grechko N 

PROVIDER: S-EPMC8236452 | biostudies-literature | 2021 Aug

REPOSITORIES: biostudies-literature